BERLIN, Nov 26 (Reuters) - Roche will acquire

California-based biopharmafirm Poseida Therapeutics ( PSTX ) for

$9 per share at closing, for a total equity value of $1 billion,

the Swiss company said on Tuesday.

Stockholders will also receive a non-tradeable contingent

value right (CVR) for $4 per share, representing a total deal

value of up to approximately $1.5 billion, said the company.

The transaction is expected to close in the first quarter of

2025.

(Writing by Miranda Murray; Editing by Tom Hogue)